Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06993116
PHASE1

A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.

Official title: A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4712 in Patients With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2025-06-09

Completion Date

2027-05

Last Updated

2026-01-28

Healthy Volunteers

No

Interventions

DRUG

SHR-4712 Injection

SHR-4712 injection.

Locations (2)

Fujian Cancer Hospital

Fuzhou, Fujian, China

Hunan Cancer Hospital

Changsha, Hunan, China